The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Official Title: A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors
Study ID: NCT01765790
Brief Summary: The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Scottsdale Healthcare, Scottsdale, Arizona, United States
Florida Cancer Specialists / Sarah Cannon Research Institute, Sarasota, Florida, United States
Department of Investigator Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, , Germany
Name: Study Director
Affiliation: Takeda
Role: STUDY_DIRECTOR